insights_auto
Π§ΠΎΠΌΡ Π²Π°ΡΡΡΡΡΡ 4142 Π·ΡΠΎΡΠ»Π° 2,45%?
ΠΡΠ·Π½Π°ΡΠΈΡΡ Π±ΡΠ»ΡΡΠ΅chevron_right
4142:TPE
Adimmune Corp
16,75Β TWD
arrow_upward
+2,45%(+0,40) 1 Π΄Π½
9 Π»ΠΈΡΡ., 11:50:06 GMT+8 · TWD
search
Π£ΡΡ ΡΠΈΠΌΠ²ΠΎΠ»ΠΈ
| Π‘ΠΈΠΌΠ²ΠΎΠ» | Π¦ΡΠ½Π° | ΠΠΌΡΠ½Π° | % Π·ΠΌΡΠ½ΠΈ |
|---|
insights_autoΠ‘ΡΠ²ΠΎΡΠ΅Π½Π½Ρ Π½Π°ΠΉΠ²Π°ΠΆΠ»ΠΈΠ²ΡΡΠΎΡ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠΈ Π΄Π»Ρ 4142β¦
ΠΡΠ΄ΠΊΡΠΈΡΠΈ
16,35Β TWD
ΠΠΈΡΠΎΠΊΠ°
17,00Β TWD
ΠΠΈΠ·ΡΠΊΠ°
16,35Β TWD
Π ΠΈΠ½ΠΊΠΎΠ²Π° ΠΊΠ°ΠΏΡΡΠ°Π»ΡΠ·Π°ΡΡΡ
7,19Β ΠΌΠ»ΡΠ΄
Π‘Π΅ΡΠ΅Π΄Π½ΡΠΉ ΠΎΠ±ΡΡΠ³
1,12Β ΠΌΠ»Π½
ΠΠ±ΡΡΠ³
531,16Β ΡΠΈΡ.
ΠΠ°ΠΉΠ²ΠΈΡΠ° Π·Π° 52 ΡΠΈΠΆΠ½Ρ
22,50Β TWD
ΠΠ°ΠΉΠ½ΠΈΠΆΡΠ° Π·Π° 52 ΡΠΈΠΆΠ½Ρ
15,65Β TWD
ΠΡΠΈΠ±ΡΡΠΎΠΊ Π½Π° Π°ΠΊΡΡΡ
-0,34Β TWD
ΠΠΊΡΡΡ Π² ΠΎΠ±ΡΠ³Ρ
235,29Β ΠΌΠ»Π½
ΠΡΠ»ΡΠΊΡΡΡΡ ΠΏΡΠ°ΡΡΠ²Π½ΠΈΠΊΡΠ²
564
ΠΡΠ΄ΠΊΡΠΈΡΠΈ
16,35Β TWD
ΠΠΈΡΠΎΠΊΠ°
17,00Β TWD
ΠΠΈΠ·ΡΠΊΠ°
16,35Β TWD
Π ΠΈΠ½ΠΊΠΎΠ²Π° ΠΊΠ°ΠΏΡΡΠ°Π»ΡΠ·Π°ΡΡΡ
7,19Β ΠΌΠ»ΡΠ΄
Π‘Π΅ΡΠ΅Π΄Π½ΡΠΉ ΠΎΠ±ΡΡΠ³
1,12Β ΠΌΠ»Π½
ΠΠ±ΡΡΠ³
531,16Β ΡΠΈΡ.
ΠΠ°ΠΉΠ²ΠΈΡΠ° Π·Π° 52 ΡΠΈΠΆΠ½Ρ
22,50Β TWD
ΠΠ°ΠΉΠ½ΠΈΠΆΡΠ° Π·Π° 52 ΡΠΈΠΆΠ½Ρ
15,65Β TWD
ΠΡΠΈΠ±ΡΡΠΎΠΊ Π½Π° Π°ΠΊΡΡΡ
-0,34Β TWD
ΠΠΊΡΡΡ Π² ΠΎΠ±ΡΠ³Ρ
235,29Β ΠΌΠ»Π½
ΠΡΠ»ΡΠΊΡΡΡΡ ΠΏΡΠ°ΡΡΠ²Π½ΠΈΠΊΡΠ²
564
ΠΠΎΠ²ΠΈΠ½ΠΈ
Π Π΄ΠΆΠ΅ΡΠ΅Π» Π² ΠΠ½ΡΠ΅ΡΠ½Π΅ΡΡ ΠΉ Π²ΡΠ΄ ΡΠ½ΡΠΎΡΠΌΠ°ΡΡΠΉΠ½ΠΈΡ
ΠΏΠ°ΡΡΠ½Π΅ΡΡΠ²
ΠΠ°ΠΊΠΎΠ½ Ρ ΠΡΠ·Π½Π΅Ρ
·
2 Π΄Π½Ρ ΡΠΎΠΌΡ
Π¨Π ΠΏΡΠ΄ Π·Π°Π³ΡΠΎΠ·ΠΎΡ: ΡΠΎΠΌΡ ΠΏΠ΅ΡΠ΅ΠΌΠΎΠ³Π° Π΄Π΅ΠΌΠΎΠΊΡΠ°ΡΡΠ² Ρ Π‘Π¨Π ΠΎΠ±ΡΡΡΠΈΠ»Π° Π°ΠΊΡΡΡ ΡΠ΅Ρ
Π³ΡΠ³Π°Π½ΡΡΠ² Π½Π° ΡΡΠΈΠ»ΡΠΉΠΎΠ½ΠΈ Π΄ΠΎΠ»Π°ΡΡΠ²
Π Π°Π΄ΡΠΎ Π‘Π²ΠΎΠ±ΠΎΠ΄Π°
·
2 Π΄Π½Ρ ΡΠΎΠΌΡ
IT-ΠΊΠΎΠΌΠΏΠ°Π½ΡΡ Π²ΡΡΠ°ΡΠΈΠ»ΠΈ ΠΌΡΠ»ΡΡΡΠ΄ΠΈ Π΄ΠΎΠ»Π°ΡΡΠ² ΡΠ΅ΡΠ΅Π· ΠΏΠ°Π΄ΡΠ½Π½Ρ Π±ΡΡΠΆΠ΅Π²ΠΈΡ
ΡΠ½Π΄Π΅ΠΊΡΡΠ²
ΠΡΠΎΡΡΠ»Ρ
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
ΠΠ½ΡΠΎΡΠΌΠ°ΡΡΡ ΠΏΡΠΎ Adimmune Corp
ΠΠ΅Π½Π΅ΡΠ°Π»ΡΠ½ΠΈΠΉ Π΄ΠΈΡΠ΅ΠΊΡΠΎΡ-
ΠΡΠ°ΡΡΠ²Π½ΠΈΠΊΠΈ564
ΠΠ°ΡΠ° Π·Π°ΡΠ½ΡΠ²Π°Π½Π½Ρ1965
ΠΠΎΠ»ΠΎΠ²Π½ΠΈΠΉ ΠΎΡΡΡ-
ΠΠ°Π»ΡΠ·ΡHealth Care
ΠΠ°Π»ΡΠ·Ρ-
ΠΠ΅Π±ΡΠ°ΠΉΡadimmune.com.tw